Revenue increased 31% for the quarter compared to same period prior year
Positive cash flows from operations of $0.35 million for the quarter
Net loss improved 59% for the quarter compared to same period prior year
Net loss per share improved 90% for the quarter compared to same period prior year
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery
- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone
-Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility
Read MoreReports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03
Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion
Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza
Announces expansion of its Executive Committee
Read MoreSecured multi-regional patent assets, strengthening Ainos' AI Nose technology.
Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.
Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts.
Read MoreCanalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA
By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree
Read More
Just a short train ride from Manhattan or a scenic drive along the Merritt Parkway, visitors can find ESSE Care’s new location at Exit 31 on North Street, set amidst the serene backdrop of back-country Greenwich.
Read More
The Behavioral Health Tech 2024 (BHT2024) conference is a premier event dedicated to advancing access to mental health, substance use, and intellectual and developmental disability (IDD) care through technology, health equity, and innovation. Scheduled for November 5th to 7th, 2024, the conference will be held at the Arizona Biltmore, LXR Hotels & Resorts in Phoenix, Arizona.
Read More
Smile Digital Health is supporting NCQA to expand the digital transformation of HEDIS® through their Smile dQM Innovation Program for NCQA Digital Content Services Early Adopters
Read MoreAdult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)
A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS
Read More
Join Donath Facial Plastic Surgery for their annual event, featuring exclusive cosmetic injection offers, expert consultations, and a chance to win Botox for a year.
Read More
Beauty-Stem Biomedical continues to make strides in preventive medicine, advancing the science of stem cell nutrition to prevent and combat cancer, alongside its valued partnership with the American Cancer Society.
Read More
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents
Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices
Read More
